CDT-WEST Center of Diagnostics and Therapy
CDT-WEST Center of Diagnostics and Therapy
Germany, Cologne
The average rhabdomyosarcoma treatment cost in Germany depends on the complex integration of diagnostics like PET/CT, which runs from $2,300 to $2,400, and primary therapies. Central procedures such as removal of rhabdomyosarcoma typically range from $50,000 to $90,000, while radiation therapy for sarcomas costs $15,000 to $22,000. Total expenses vary by tumor stage and clinic tier. Patients often find 40-60% savings compared to the US. Key medical centers are located in Berlin, Hamburg, and Cologne.
Typical Rhabdomyosarcoma Treatment Costs in Germany
Bookimed Expert Insight: Pediatric patients requiring specialized care should consider Charité Berlin, where Professor Angelika Eggert leads the pediatric oncology department. For tumors near vital organs, CDT-WEST in Cologne offers advanced IGRT and DIBH technologies. Asklepios Nord Clinic is ideal for families seeking multidisciplinary support. It is a top-ranked German hospital treating over 72,000 patients annually.
| Germany | Turkey | Austria | |
| Removal of rhabdomyosarcoma | from $50,000 | from $15,000 | from $30,000 |
| Radiation therapy for colorectal cancer | from $20,000 | from $7,000 | from $12,000 |
| Radiation Therapy for Sarcomas | from $15,000 | from $3,250 | from $18,000 |
| Chemotherapy for breast cancer | from $4,500 | from $1,200 | from $15,000 |
| Complex treatment of rhabdomyosarcoma | - | from $45,000 | - |
No hidden fees – just official clinic prices. Pay at the clinic for Rhabdomyosarcoma treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Rhabdomyosarcoma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Rhabdomyosarcoma treatment journey.
Prof. Angelika Eggert leads the Department of Pediatric Oncology at Charité – Universitätsmedizin Berlin, specializing in childhood cancers.
The doctor is the Chief Physician of the Oncology and Hematology Center at Bremen Mitte Hospital, specializing in hematological malignancies and gastrointestinal tract tumors. Completing a specialization in immunology in 1987, the doctor earned a doctorate at the Internal Medicine Department of Bremen Mitte Hospital in 1993. In 2007, the doctor became a senior physician at the Internal Medicine Center Bremen Mitte. Since 2005, the doctor has led the Oncology Center and lectured on innovative cancer therapy at the Bremen Oncology Society.
The doctor is a member of several prestigious organizations, including the German Society of Hematology and Medical Oncology and the German Cancer Society.
The doctor is an experienced radiotherapist at the Essen University Hospital, specializing in the treatment of malignant tumors and benign disorders. The clinical focus includes multimodal interdisciplinary treatment of lung cancer, breast cancer, prostate cancer, sarcomas, malignant lymphomas, and pediatric tumors.
Expertise in stereotactic radiotherapy for brain tumors and the use of the latest technical equipment for image-guided intensity-modulated radiotherapy is highlighted. The doctor also employs gated radiotherapy for lung tumors and utilizes afterloading units and telecobalt machines for total body radiation prior to bone marrow transplants.
Research interests include radiation sensitivity, repair/resistance mechanisms of human tumor cells, and image-guided radiotherapy.
The doctor is a highly rated gastroenterologist in Europe, recognized among the TOP 100 doctors in Germany for GI lesion treatment. The doctor contributes to the development of German guidelines for esophageal cancer treatment and specializes in gastrointestinal tract tumors.
Since 2000, the doctor has served as Director of the Clinic for Internal Medicine at Bremen-Ost Clinic in Germany. Previous roles include researcher positions at the MD Anderson Cancer Institute and Heinrich Heine University. The doctor holds a Clinical Award for Gastroenterology and a Merit Award from the Gastrointestinal Cancers Symposium.
Standard treatment follows a multimodal framework regulated by the Cooperative Weichteilsarkom Studiengruppe (CWS). This risk-stratified protocol combines ifosfamide-based chemotherapy with surgery and precision radiation. German centers like Charite Universitätsmedizin Berlin integrate systemic therapy with local control to maximize outcomes.
Bookimed Expert Insight: German university hospitals demonstrate a high degree of specialization for complex oncology. Charite Universitätsmedizin Berlin serves over 840,000 patients yearly with Prof. Dr. Angelika Eggert leading pediatric oncology. This high patient volume ensures clinicians manage even rare alveolar subtypes using the latest CWS registry data. Choosing centers with DIBH or IGRT technology is crucial for tumors located near vital organs.
Patient Consensus: Patients note that chemotherapy is almost always the first step to shrink tumors. They emphasize that radiation is often necessary even if surgery appears completely successful.
Proton beam therapy is highly established for pediatric rhabdomyosarcoma in Germany. Specialized particle therapy centers use this treatment for tumors near critical structures like the brain or spine. This approach minimizes damage to healthy tissue. It helps protect a child's long-term growth and development.
Bookimed Expert Insight: Germany ranks second globally in medical requests on our platform with over 2,214 served. Large academic centers like Charité Berlin treat over 5,600 children annually across all departments. This high volume allows pediatric oncologists like Dr. Angelika Eggert to manage rare cases effectively. Families should prioritize university hospitals where research and proton technology are integrated for better outcomes.
Patient Consensus: Patients emphasize the importance of choosing centers based on the tumor's location, especially for sensitive areas like the eyes. Many note that proton therapy requires a dedicated daily schedule and may involve sedation for younger children.
German oncology centers report 5-year survival rates exceeding 80% for localized pediatric rhabdomyosarcoma. Success depends on CWS protocols and multimodal therapy. Intermediate-risk cases show 50% to 70% survival. Metastatic or relapsed cases typically see survival rates under 30% in specialized units.
Bookimed Expert Insight: While Germany ranks second globally in our network for patient requests, its strength lies in university hospitals like Charite University Hospital Berlin. Dr. Angelika Eggert leads their pediatric oncology, managing over 5,600 children annually. This high volume is critical for rare diseases like rhabdomyosarcoma. Choosing these academic centers ensures access to the latest CWS protocols and multidisciplinary teams that general hospitals often lack.
Patient Consensus: Patients emphasize that getting a second opinion from a pediatric sarcoma specialist is vital. They note that survival expectations vary significantly based on whether the tumor is embryonal or alveolar.
German oncology protocols utilize maintenance chemotherapy primarily for high-risk rhabdomyosarcoma cases to prevent relapse. Specialized university hospitals follow evidence-based guidelines from the German Society of Hematology and Medical Oncology. This phase typically involves lower-intensity drugs after intensive induction and consolidation cycles are complete.
Bookimed Expert Insight: Data from major German centers like Charité Universitätsmedizin Berlin shows a heavy reliance on protocol-driven care. While smaller clinics may offer standard diagnostics, the 4,000+ doctors at Charité handle rare pediatric sarcomas using specific European registries. If a patient does not qualify for maintenance under these strict criteria, teams often prioritize observation to avoid unnecessary toxicity. This highlights why seeking an initial consultation at a university hospital with a dedicated pediatric oncology head, such as Dr. Angelika Eggert, is vital for high-risk cases.
Patient Consensus: Families note that maintenance is not an automatic extra phase for every patient. Many clarify with their teams whether the next step is active maintenance or observation based on individual scan results.
Treatment for rhabdomyosarcoma in Germany follows a centralized coordination system guided by the Cooperative Soft Tissue Sarcoma Study Group. Specialized pediatric oncology centers use standardized protocols like SoTiSaR. This framework ensures uniform care across multidisciplinary tumor boards and reference diagnostic centers.
Bookimed Expert Insight: Germany holds the number 2 global rank in our market data for complex oncology cases. This high volume supports specialized institutions like Charité - Universitätsmedizin Berlin, which manages over 5,600 pediatric cases annually. Patients benefit most when selecting hospitals that conduct active clinical trials, as these centers often provide the most rigorous adherence to the latest CWS study protocols.
Patient Consensus: Patients note that care is organized through entire oncology departments rather than single doctors. Many are surprised to learn that chemotherapy often precedes surgery to shrink tumors for safer removal.